Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval

Acute myelogenous leukemia (AML) represents the most common indication for allogeneic hematopoietic stem cell transplantation (allo-HSCT) worldwide [1]. Despite major progresses in our understanding of AML biology and the recent arrival of emerging targeted therapies to the field, allo-HSCT remains the first-choice consolidation strategy for fit patients in first remission who are at a high risk of relapse [2,3,4]. Moreover, allo-HSCT is the only therapeutic option resulting in significant long-term survival rates in patients with refractory or relapsed disease [5].

Source: Biology of Blood and Marrow Transplantation - August 25, 2018 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Francisco José Márquez-Malaver, Nancy Rodríguez-Torres, Teresa Caballero-Velázquez, Virginia Escamilla-Gómez, Cristina Calderón-Cabrera, José Francisco Falantes-González, María Solé-Rodríguez, Patricia García-Ramí Source Type: research